The Internets got agitated recently at the news that Moderna’s CEO, Stephane Bancel, dumped $400Million in Moderna stocks and nuked his Twitter account. Here’s why this shouldn’t surprise you and you should expect the worst any moment now.

Developing story, to be updated

Have you watched the former Blackrock director that went on Bannon’s War Room and prophesied that the Covid vaccines are a bubble that’s about to pop? Everything I’ve learned lately stands to support his claim.

This is him on Twitter:

If the dumping were a sudden and unusual move, this would indicate a recent event that shook the system, possibly rats leaving a sinking ship, a near threat for the business, as in:

That’s the case only partly, due to the stock crash overlapped with the incoming financial report, but a constant behavior over the span of months and years rather indicate a strategy and it’s associated with insider trading more often than not.

Surprisingly, it’s NPR of all the fakestream media who came in support of my suspicions, with a pretty merciless analysis of Moderna’s leadership financial behavior. And you know what’s funny? The piece dates all the way back to September 2020. I recommend reading the whole piece, I added the bolding and highlights :

Whether the coronavirus vaccine developed by Moderna succeeds or not, executives at the small biotech company have already made tens of millions of dollars by cashing in their stock. An NPR examination of official company disclosures has revealed additional irregularities and potential warning signs.

“On a scale of one to 10, one being less concerned and 10 being the most concerned,” said Daniel Taylor, an associate professor of accounting at the Wharton School, “this is an 11.”

Taylor said Moderna’s stock-selling practices appear well outside the norm, and raise questions about the company’s internal controls to prevent insider trading.

Since January, CEO Stéphane Bancel has sold roughly $40 million worth of Moderna stock held by himself or associated investment funds; Chief Medical Officer Tal Zaks has sold around $60 million; and President Stephen Hoge has sold more than $10 million.

Stéphane Bancel, chief executive officer of Moderna, has sold roughly $40 million worth of stock in the company since the beginning of this year.

The stock sales first came to widespread notice after Moderna announced positive early data from a vaccine trial in May [2020 – S.m.]. At that point, the company’s share price jumped and official disclosures showed executives cashing in their shares for millions of dollars.

“As long as stocks are sold after public announcements – and not before – one might conclude that for an executive with significant net worth tied up in the company, it’s a prudent thing to do,” said Marc Fagel, a former longtime enforcement official with the Securities And Exchange Commission (SEC). “But the optics aren’t great.”

The Moderna vaccine was quick to reach a phase 3 trial, and is seen as a promising contender. But, in some ways, the executives’ stock sales have overshadowed the company’s progress.

Advocates have questioned whether it’s appropriate for executives to privately profit before bringing the vaccine to market, especially when American taxpayers have committed roughly $2.5 billion to the company’s vaccine development and manufacture.

Here’s what NPR’s examination found:

  • Stock Sales Worth Tens Of Millions: Since June 1, NPR has found, company executives have sold roughly $90 million worth of Moderna stock. Rather than put a hold on the trades after facing intense criticism in May, company executives continued to sell.
  • Questionable Modifications To Stock Sale Plans: Moderna says its executives pre-scheduled their stock sales long in advance. Those schedules – known as 10b5-1 plans – can act as a defense to charges of insider trading. But the plans have to be put in place when executives do not have confidential inside information. NPR has found multiple executives adopted or modified their plans just before key announcements about the company’s vaccine. That has raised questions about whether they were aware of nonpublic information when they planned their stock trades.
  • Selling To Zero: Generally, corporate best practices suggest that a company’s leadership should hold on to at least some stock in their company to have “skin in the game.” That way, the thinking goes, an executive has an incentive to improve the company’s performance. As Moderna has been developing its coronavirus vaccine, two executives, including the Chief Medical Officer, have sold all their stock holdings in the company. The General Counsel has sold nearly all of her holdings.

In an interview with NPR, Ray Jordan, Moderna’s Chief Corporate Affairs Officer, said the company has strict internal policies in place to prevent illegal insider trading. For example, Jordan said, the company only allows employees to make changes to their stock sale schedules when they don’t have confidential inside information that could affect the company’s share price.

NPR asked Jordan why Moderna executives modified their 10b5-1 plans just before major announcements. Initially, Jordan said by email, “I believe you must have your dates wrong.”

NPR then provided documentation of those dates from the company’s official disclosures to the government, which Jordan did not dispute.

Jordan then said that even though multiple Moderna executives changed their 10b5-1 plans within one business day of announcements, the company had determined that those executives did not have “material nonpublic information” – a key term for insider trading – when they made those changes.

A spokesperson for the SEC declined to comment for this story.

From a relative unknown, to a key player in the vaccine race

Moderna launched in 2010 with a headquarters based in Cambridge, Mass., focused on using a technology called messenger RNA (or mRNA) to develop vaccines and therapeutics. The mRNA technology has been widely considered innovative, but remains largely unproven. The company has never brought a product to market. In early January, Moderna was trading for under $20 per share, and was valued at around six billion dollars.

Then Moderna announced that it had started collaborating on a coronavirus vaccine with scientists from the National Institute of Allergy and Infectious Diseases, which is led by Dr. Anthony Fauci.

By April, the government had committed half a billion dollars to the Moderna vaccine project as part of Operation Warp Speed.

Since then, the company’s stock price has exploded. Press releases suggesting positive news from the scientific trials, or announcing additional commitments of taxpayer funding sent the share price to a peak of around $95, before dropping to between $60-$70 in recent months. The company is now valued at around $25 billion.

As a result, shares owned by Moderna executives suddenly became much more valuable. And those executives have cashed in tens of millions of dollars worth of stock, according to filings with the SEC.

The bad press and critical comments did not deter continued sales. Since June 1, NPR found, executives sold around $90 million worth of stock.

Public money, private gain

The U.S. government is making massive financial bets on several vaccine candidates. In all likelihood, only some of those vaccine candidates will prove sufficiently safe and effective.

“If the vaccine doesn’t work, you lost a lot of money,” Fauci has said. “But we feel this is serious enough that it’s worth the financial risk.”

But even if taxpayers lose money betting on Moderna, the company’s executives have already made millions.

“The insiders are making plenty of profit and they’re mostly doing it with our money,” said Margarida Jorge, a campaign director with the group Lower Drug Prices Now. “I’m absolutely for deploying public money in the interests of public health and the public good. But we don’t have any commitment from the administration that any of this investment is ultimately going to benefit real people.”

Moderna has argued that the company was only in a position to work with the government on a coronavirus vaccine, because it had spent a decade developing its mRNA technology with the support of private investors.

“The company has been funded over the years by billions of dollars of private investment,” Zaks told the Freakonomics podcast in August. “Those billions created the opportunity for the U.S. government to come in earlier this year and say, ‘I’m going to add some money to the pot to make sure that you get the development for this vaccine right.'”

[But they locked in the Government and its funding for mRNA technology years before SARS-COV2, as shown below, so this was a deliberate lie – S.m]
Trying to resuscitate the company with some archive work?

“Set it and forget it” stock plans

Moderna has offered another defense of those stock sales: the sales, representatives and executives say, were scheduled well in advance, and were unrelated to the market-moving announcements about the coronavirus vaccine. An NPR examination of the company’s financial filings tells a more complicated story.

The schedules are known as 10b5-1 plans. If your stock trades are on autopilot, the idea goes, then you can’t be accused of insider trading. But these “set it and forget it” plans have to be adopted when executives do not have “material nonpublic information,” to use the legal term.

In an interview with CNBC in July, CEO Bancel said he and other executives set up their 10b5-1 plans “a long time ago” – in December 2018 – and “obviously, when we set up those plans, none of us had any idea what was going to happen in 2020.”

In fact, NPR has found, Moderna executives, including Bancel himself, implemented new plans or modified older plans at multiple points in 2020, and right around key announcements related to the company’s vaccine.

On Jan. 21, 2020, for example, Chief Medical Officer Dr. Tal Zaks amended his 10b5-1 plan. (It’s unclear what changes he made.)

Then, on Jan. 22, Moderna first widely confirmed that it was working with the government on a coronavirus vaccine. The following day, Jan. 23, the company announced it had received additional funding to support its coronavirus vaccine development.

NPR asked Moderna whether Zaks might have been aware of the collaboration with the government when he changed his stock trading plan.

“What was known on that particular day or not known, I couldn’t specifically talk to,” Moderna’s Jordan told NPR. But he said that the Moderna legal team only allows employees to change their 10b5-1 plans if they do not possess inside information that could affect the company’s share price.

Later, on Friday, March 13, three Moderna executives adopted new 10b5-1 plans, according to records reviewed by NPR: Zaks, Chief Technical Operations and Quality Officer Juan Andres, and then-Chief Financial Officer Lorence H. Kim. (Kim left the company in August 2020.)

On Monday, March 16 – one business day later – the company announced that it had given a participant the first dose of their vaccine as part of its phase 1 trial. The stock ended that day up 24% compared to the previous day’s close. Moderna was “bucking the trend” of the broader market, which was panicking over coronavirus fears, one CNBC host said at the time.

Timing Of Changes To Pre-Scheduled Stock Sales Raises Questions

Jan. 21 – Chief Medical Officer Dr. Tal Zaks amends his schedule of stock sales, known as a 10b5-1 plan.

Jan. 22 – Moderna widely confirms that it is working on a coronavirus vaccine with the National Institutes of Health. The company’s share price rises nearly 5% over the previous day’s close.

Jan. 23 – Moderna announces new funding from the Coalition for Epidemic Preparedness Innovations.

Mar. 13 – Chief Technical Operations Officer Juan Andres, Chief Financial Officer Lorence Kim, and Zaks adopt new 10b5-1 trading plans.

Mar. 16 – Moderna announces that it provided the first dose of its coronavirus vaccine to a participant in a phase 1 trial. Moderna stock climbs 24% over the previous day’s close.

May 18 – Moderna reports early positive data from its phase 1 trial. The company’s stock ends the day up 20% over the previous day’s close.

May 21 – CEO Stéphane Bancel adopts and amends multiple 10b5-1 trading plans.

May 29 – Moderna announces another milestone in its phase 2 coronavirus vaccine trial.

June 1 – President Stephen Hoge amends his 10b5-1 plan.

Despite the close timing, Jordan told NPR, “by the judgment of the legal team, there would not have been material, nonpublic information known” when executives entered into the new plans.

“Every company and individual is entitled to the presumption of innocence. That said, from the public’s perspective, this trading behavior looks very problematic,” said Taylor of the Wharton School, who first pointed out the timing of these changes to NPR.

“If I put on my SEC enforcement hat, I would certainly be asking, ‘What caused you to change the plan on a Friday?'” said Kurt Wolfe, who works as a defense attorney in securities cases for the firm Troutman Pepper. “I don’t think it’s a good fact pattern.”

On May 21 – in between announcements of major vaccine trial milestones on May 18 and May 29 – CEO Bancel amended and adopted 10b5-1 plans. And on June 1, President Hoge amended his trading plan.

“Amending a trading plan after a positive announcement, like trading after a positive announcement, is only problematic if the executive possesses material, nonpublic information at the time,” said Fagel. “Though repeated or questionably-timed changes to a trading plan will reduce its value as a defense to insider trading.”

Selling to zero

Using these 10b5-1 plans, two Moderna executives – Zaks and Andres – have sold all of their shares in the company. General Counsel Lori Henderson has sold nearly all of her shares.

In fact, roughly every week since June, Zaks has exercised stock options (meaning, he bought stock at a price set by the company as part of his compensation), and then immediately sold all of his shares for a significant profit.

[Isn’t this a great explanation for Bancel’s sales too?! – S.m]


On Aug. 24, for example, Zaks exercised stock options and bought 25,000 shares at bargain prices of between $12 to $21. He then immediately sold all of those shares for around $65 per share. Zaks ended up with a profit of nearly $1.2 million.

SEC filings indicate these trades are made under the 10b5-1 plan he adopted in March.

Selling so much stock can also raise concerns for investors – and the public – about why company leaders would sell now if they expected their vaccine to succeed later. After all, a safe and effective vaccine could send Moderna’s stock to even greater heights.

“It perhaps draws questions about how much they believe in it,” said Wolfe.

If the company does develop a safe and effective coronavirus vaccine, and its stock keeps rising, then “these trades will be water under the bridge,” said Fagel, the former SEC enforcement official.

But, Fagel warns, if the vaccine fails, then SEC regulators and angry investors may come looking for answers. In that case, he said, “both class action litigation and an SEC investigation would seem inevitable.”

NPR revelations end here, we’re actually just starting

So what we’ve learned is that Moderna looks like a stock market operation more than a medical one. The chiefs create momentums and then trade. And they use public money to bet and make billions, but more about that shortly.

This news is actually pretext to get you to know the real history of Moderna, a crux point in modern history in the widest sense. The stock dumping is not really news, it’s been happening for quite a while, indicating a long term strategy and business model, rather than a sudden or impulse move.

The next two older reports from Pharma’s own media – STAT, will cement the certainty that Moderna turned into a stock market bubble long ago, under the helms of Stephan Bancel. They don’t mind having some science to show, but that’s just the bait.

Ego, ambition, and turmoil: Inside one of biotech’s most secretive startups

By Damian Garde for STAT, Sept. 13, 2016

At first glance, Moderna Therapeutics looks like the most enviable biotech startup in the world. It has smashed fundraising records and teamed up with pharmaceutical giants as it pursues a radical plan to revolutionize medicine by transforming human cells into drug factories.

But the reality is more complicated.

A STAT investigation found that the company’s caustic work environment has for years driven away top talent and that behind its obsession with secrecy, there are signs Moderna has run into roadblocks with its most ambitious projects.

At the center of it all is Stéphane Bancel, a first-time biotech CEO with an unwavering belief that Moderna’s science will work — and that employees who don’t “live the mission” have no place in the company. Confident and intense, Bancel told STAT that Moderna’s science is on track and, when it is finally made public, that it will meet the brash goal he himself has set: The new drugs will change the world.

But interviews with more than 20 current and former employees and associates suggest Bancel has hampered progress at Moderna because of his ego, his need to assert control and his impatience with the setbacks that are an inevitable part of scienceModerna is worth more than any other private biotech in the US, and former employees said they felt that Bancel prized the company’s ever-increasing valuation, now approaching $5 billion, over its science.

As he pursued a complex and risky strategy for drug development, Bancel built a culture of recrimination at Moderna, former employees said. Failed experiments have been met with reprimands and even on-the-spot firings. They recalled abusive emails, dressings down at company meetings, exceedingly long hours, and unexplained terminations.

At least a dozen highly placed executives have quit in the past four years, including heads of finance, technology, manufacturing, and science. In just the past 12 months, respected leaders of Moderna’s cancer and rare disease programs both resigned, even though the company’s remarkable fundraising had put ample resources at their disposal. Each had been at the company less than 18 months, and the positions have yet to be filled.

Lower-ranking employees, meanwhile, said they’ve been disappointed and confused by Moderna’s pivot to less ambitious — and less transformative — treatments. Moderna has pushed off projects meant to upend the drug industry to focus first on the less daunting (and most likely, far less lucrative) field of vaccines — though it is years behind competitors in that arena.

The company has published no data supporting its vaunted technology, and it’s so secretive that some job candidates have to sign nondisclosure agreements before they come in to interview. Outside venture capitalists said Moderna has so many investors clamoring to get in that it can afford to turn away any who ask too many questions. Some small players have been given only a peek at Moderna’s data before committing millions to the company, according to people familiar with the matter.

“It’s a case of the emperor’s new clothes,” said a former Moderna scientist. “They’re running an investment firm, and then hopefully it also develops a drug that’s successful.”

Like many employees and former employees, the scientist requested anonymity because of a nondisclosure agreement. Others would not permit their names to be published out of fear that speaking candidly about big players in the industry would hurt their job prospects down the road.

Moderna just moved its first two potential treatments — both vaccines — into human trials. In keeping with the culture of secrecy, though, executives won’t say which diseases the vaccines target, and they have not listed the studies on the public federal registry, ClinicalTrials.gov. Listing is optional for Phase 1 trials, which are meant to determine if a drug is safe, but most companies voluntarily disclose their work.

Investors say it’ll be worth the wait when the company finally lifts the veil.

“We think that when the world does get to see Moderna, they’re going to see something far larger in its scope than anybody’s seen before,” said Peter Kolchinsky, whose RA Capital Management owns a stake in the company.

Moderna
The Moderna offices in Cambridge, Mass.ARAM BOGHOSIAN FOR STAT

Bancel, meanwhile, said he is aware of the criticism of him and has taken some steps to address it. After scathing anonymous comments about Moderna’s management began showing up online, Bancel went to Silicon Valley to get tips on employee retention from the human resources departments of Facebook, Google, and Netflix. But he makes no apologies for tumult past or present, pointing to the thousands of patients who might be saved by Moderna’s technology.

“You want to be the guy who’s going to fail them? I don’t,” he said in an interview from his glassy third-floor office. “So was it an intense place? It was. And do I feel sorry about it? No.”

An ambitious CEO dreams big

Bancel, 44, had no experience running a drug development operation when one of biotech’s most successful venture capitalists tapped him to lead Moderna. He’d spent most of his career in sales and operations, not science.

But he had made no secret of his ambition.

A native of France, Bancel earned a master’s in chemical engineering from the University of Minnesota and an MBA from Harvard in 2000. As Harvard Business School classmates rushed to cash in on the dot-com boom, Bancel laid out a plan to play “chess, not checkers.”

“I was always thinking, one day, somebody will have to make a decision about me getting a CEO job,” he told an audience at his alma mater in April. “… How do I make sure I’m not the bridesmaid? How do I make sure that I’m not always the person who’s almost selected but doesn’t get the role?”

He went into sales and rose through the operational ranks at pharmaceutical giant Eli Lilly, eventually leading the company’s Belgian operation. And in 2007, at just 34, he achieved his goal, stepping in as CEO of the French diagnostics firm bioMérieux, which employs roughly 6,000 people.

The company improved its margins under Bancel’s tenure, and he developed a reputation as a stern manager who got results, according to an equities analyst who covered bioMérieux at the time.

“He doesn’t suffer fools lightly,” the analyst said, speaking on condition of anonymity to comply with company policy. “I think if you’re underperforming, you’ll probably find yourself looking for another job.”

Bancel’s rise caught the eye of the biotech investment firm Flagship Ventures, based here in Cambridge. Flagship CEO Noubar Afeyan repeatedly tried to entice him to take over one of the firm’s many startups, Bancel said. But he rejected one prospect after another because the startups seemed too narrow in scope.

Moderna was different.

The company’s core idea was seductively simple: cut out the middleman in biotech.

For decades, companies have endeavored to craft better and better protein therapies, leading to new treatments for cancer, autoimmune disorders, and rare diseases. Such therapies are costly to produce and have many limitations, but they’ve given rise to a multibillion-dollar industry. The anti-inflammatory Humira, the world’s top drug at $14 billion in sales a year, is a shining example of protein therapy.

Moderna’s technology promised to subvert the whole field, creating therapeutic proteins inside the body instead of in manufacturing plants. The key: harnessing messenger RNA, or mRNA.

In nature, mRNA molecules function like recipe books, directing cellular machinery to make specific proteins. Moderna believes it can play that system to its advantage by using synthetic mRNA to compel cells to produce whichever proteins it chooses. In effect, the mRNA would turn cells into tiny drug factories.

It’s highly risky. Big pharma companies had tried similar work and abandoned it because it’s exceedingly hard to get RNA into cells without triggering nasty side effects. But if Moderna can get it to work, the process could be used to treat scores of diseases, including cancers and rare diseases that can be death sentences for children.

Bancel was intrigued. He knew it was a gamble, he told STAT, “but if I don’t do it, and it works, I’m just going to kick myself every morning.”

And so he became the company’s CEO — and soon developed an almost messianic reverence for the mRNA technology.

Despite having never worked with RNA before, Bancel said he sat around the table with his core team in the early days of the company, dreaming up experiments. As a result, he is listed as a co-inventor on more than 100 of Moderna’s early patent applications, unusual for a CEO who is not a PhD scientist.

Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine

By Damian Garde, STAT, Jan. 10, 2017

SAN FRANCISCO — Moderna Therapeutics, the most highly valued private company in biotech, has run into troubling safety problems with its most ambitious therapy, STAT has learned — and is now banking on a mysterious new technology to keep afloat its brash promise of reinventing modern medicine.

Exactly one year ago, Moderna CEO Stéphane Bancel talked up his company’s “unbelievable” future before a standing-room-only crowd at the annual J.P. Morgan Healthcare Conference here. He promised that Moderna’s treatment for a rare and debilitating disease known as Crigler-Najjar syndrome, developed alongside biotech giant Alexion Pharmaceuticals, would enter human trials in 2016.

It was to be the first therapy using audacious new technology that Bancel promised would yield dozens of drugs in the coming decade.

But the Crigler-Najjar treatment has been indefinitely delayed, an Alexion spokeswoman told STAT. It never proved safe enough to test in humans, according to several former Moderna employees and collaborators who worked closely on the project. Unable to press forward with that technology, Moderna has had to focus instead on developing a handful of vaccines, turning to a less lucrative field that might not justify the company’s nearly $5 billion valuation.

“It’s all vaccines right now, and vaccines are a loss-leader,” said one former Moderna manager. “Moderna right now is a multibillion-dollar vaccines company, and I don’t see how that holds up.”

Bancel made no mention of the Crigler-Najjar drug when he spoke Monday before a similarly packed room at this year’s J.P. Morgan conference.

His presentation instead focused on four vaccines that the company is moving through the first phase of clinical trials: two target strains of influenza, a third is for Zika virus, and the fourth remains a secret. Bancel clicked through graphs of data from animal studies before hurrying on to tout Moderna’s balance sheet and discuss the company’s cancer vaccines, slated for clinical testing later this year.

When STAT asked Bancel after the presentation about Crigler-Najjar, he deferred to Alexion.

In need of a Hail Mary

Founded in 2012, Moderna reached unicorn status — a $1 billion valuation — in just two years, faster than Uber, Dropbox, and Lyft, according to CB Insights. The company’s premise: Using custom-built strands of messenger RNA, known as mRNA, it aims to turn the body’s cells into ad hoc drug factories, compelling them to produce the proteins needed to treat a wide variety of diseases.

But mRNA is a tricky technology. Several major pharmaceutical companies have tried and abandoned the idea, struggling to get mRNA into cells without triggering nasty side effects.

Bancel has repeatedly promised that Moderna’s new therapies will change the world, but the company has refused to publish any data on its mRNA vehicles, sparking skepticism from some scientists and a chiding from the editors of Nature.

The indefinite delay on the Crigler-Najjar project signals persistent and troubling safety concerns for any mRNA treatment that needs to be delivered in multiple doses, covering almost everything that isn’t a vaccine, former employees and collaborators said.

The company did disclose a new technology on Monday that it says will more safely deliver mRNA. It’s called V1GL. Last month, Bancel told Forbes about another new technology, N1GL.

But in neither case has the company provided any details. And that lack of specificity has inevitably raised questions.

Three former employees and collaborators close to the process said Moderna was always toiling away on new delivery technologies in hopes of hitting on something safer than what it had. (Even Bancel has acknowledged, in an interview with Forbes, that the delivery method used in Moderna’s first vaccines “was not very good.”)

Are N1GL and V1GL better? The company has produced no data to answer that question. When STAT asked about new technologies, Bancel referred questions to the company’s patent filings.

The three former employees and collaborators said they believe N1GL and V1GL are either very recent discoveries, just in the earliest stages of testing — or else new names slapped on technologies Moderna has owned for years.

“[The technology] would have to be a miraculous, Hail Mary sort of save for them to get to where they need to be on their timelines,” one former employee said. “Either [Bancel] is extremely confident that it’s going to work, or he’s getting kind of jittery that with a lack of progress he needs to put something out there.”

Former employees and collaborators who spoke with STAT requested anonymity because they had signed nondisclosure agreements — which the highly secretive Moderna requires even some job candidates to sign.

STAT investigation last year found that Bancel had driven away top talent from Moderna with a culture of recrimination and a caustic work environment, including on-the-spot firings for failed experiments.

The company, based in Cambridge, Mass., seems to have repaired its reputation among many rank-and-file employees, winning workplace accolades from Science Magazine and the Boston Globe, but Moderna has lost more than a dozen top scientists and managers in the past four years, despite its vast financial resources.

A bug in the software

Bancel, a first-time biotech CEO, has dismissed questions about Moderna’s potential. He describes mRNA as a simple way to develop treatments for scores of ailments. As he told STAT over the summer, “mRNA is like software: You can just turn the crank and get a lot of products going into development.”

Related: SOFTWARE OF LIFE™ IS A MODERNA TRADE MARK FOR MRNA. LITERALLY. AND THEY MAKE APPS

It seems clear, however, that the software has run into bugs.

Patients with Crigler-Najjar are missing a key liver enzyme needed to break down bilirubin, a yellowish substance that crops up in the body as old red blood cells break down. Without that enzyme, bilirubin proliferates in the blood, leading to jaundice, muscle degeneration, and even brain damage.

In Moderna’s eyes, the one-in-million disease looked like an ideal candidate for mRNA therapy. The company crafted a string of mRNA that would encode for the missing enzyme, believing it had hit upon an excellent starting point to prove technology could be used to treat rare diseases.

But things gradually came apart last year.

Every drug has what’s called a therapeutic window, the scientific sweet spot where a treatment is powerful enough to have an effect on a disease but not so strong as to put patients at too much risk. For mRNA, that has proved elusive.

STAT
mRNA jabs are “rewriting the Genetic Code” we call it “information therapy” – Tal Zaks (Ted 2017)

Before COVID-19, the company’s secretive nature, and its failure to deliver a functional product, was drawing comparisons to the infamous biotech startup Theranos. Similar to Moderna, Theranos rarely published any peer-reviewed material. Like Moderna, Theranos mastered the networking game, and recruited high profile individuals to its board in order to vouch for the company’s “revolutionary technologies.” Once valued at well over $10 Billion, Theranos collapsed after it was revealed that the company was running a massive fraud scheme, in addition to its failure to implement its promised blood testing technology.

Jordan Schachtel @JordanSchachtelIn 2015, Dr John Ioannidis published a paper calling attention to Theranos & the shady biotech unicorn industry. Moderna is mentioned as a company that is following the Theranos path of zero disclosures, & publishing zero papers on their “innovative” tech. onlinelibrary.wiley.com/doi/epdf/10.11…
April 15th 2021113 Retweets281 Likes

Moderna’s Mysterious Medicines

FORBES EDITORS’ PICK |Dec 14, 2016

Excerpts:

“Now an obscure lawsuit filed in British Columbia in October sheds light on one of Moderna’s key partners, and through it FORBES can reveal details on Moderna’s amazing but still untested technology.

It appears that the first two products Moderna has entered into clinical trials rely on technology from a small outfit in Vancouver, British Columbia, called Acuitas Therapeutics. (Acuitas is so small, in fact, that its worldwide headquarters are in its CEO’s single-family home.)

Almost all medicines either block proteins–the building blocks of life–or, in the case of expensive biotech drugs, are proteins themselves. But Moderna has been promising to hack an entirely different part of life’s cookbook. In order to turn genetic information encoded in DNA into the cellular machines that actually are proteins, living things use a messenger chemical called mRNA.

Creating these mRNA drugs is a big challenge on many levels. For them to work, Moderna needs to deliver mRNA to the body’s cells. By itself mRNA breaks down in the bloodstream. Tiny Acuitas specializes in one method: lipid-nanoparticle delivery systems. Its technology essentially wraps the mRNA into balls of fat that disguise the drug so that the target cells will readily ingest it.

“Although we are small,” says Thomas Madden, chief executive of Acuitas, “I believe the technology we have developed is highly effective.”

The problem for Madden and Moderna is that Acuitas doesn’t actually own the technology it has licensed to Moderna. The tech belongs to a third company, publicly traded Arbutus, which recently decided to terminate the license for the tech that it had granted to Acuitas. That’s why Acuitas filed the lawsuit in British Columbia, to protect the deal it had. Arbutus immediately countersued, claiming its deal with Acuitas didn’t cover Moderna’s medicines.

The legal mess has its roots in Moderna’s 2011 start, when Robert Langer, an MIT professor, Moderna board member and founder of dozens of biotech companies, told Bancel that Moderna was too underfunded and small to create its own delivery system. So Moderna vetted over a dozen external delivery methods for mRNA and settled on at least three. One belonged to Arbutus, but Moderna turned to tiny Acuitas to get access to it.

Acuitas was formed in 2009 by Madden after a merger eliminated his position at Arbutus’ predecessor, Tekmira Pharmaceuticals. After a contentious lawsuit Madden was able to license from his former employer the novel tech he had helped develop, and Bancel claims Moderna chose to work with Acuitas because it had “the people and the capabilities.”

But that doesn’t explain why Moderna–flush with capital–didn’t make sure that sublicensing through Acuitas would be okay with Arbutus before advancing its new drugs into human studies.

Bancel met with FORBES at a Brooklyn coffee shop on a recent Saturday to dispel the implications of the lawsuit. He is dismissive of Acuitas’ technology. “We knew it was not very good,” he says. “It was just okay.”

He further explains that Moderna is in the process of producing its own nanoparticle lipids. One such lipid, N1GEL (called “Nigel” internally), appears to cause less inflammation than Acuitas’ version. Another is being licensed from Merck. Bancel says Moderna has stopped using the Acuitas tech for new drugs.

That still leaves a somewhat messy situation for any Moderna vaccines that are being developed using Acuitas’ tech.

Data from one vaccine is expected early next year. If results are good, it could lead to a sizzling-hot initial public offering, even if the Canadian lawsuit ultimately affords Arbutus bigger royalty payments from Moderna.”

Well, the two tiny Canadian companies mentioned above bring royalties to the Canada’s treasury (should I say The British Crown?), so don’t expect Trudeau to backpedal too soon

AND IF ONLY THEY HUSSLED WITH PRIVATE FUNDS, AS THEY CLAIMED…

Moderna chief keep claiming that they started to use public funds only as a patch on infrastructure, science and funding they’ve built for years.

Wrong!

It’s known that NIH + NIAID have long been one of their main sources for the “lavish funding” mentioned earlier and when they locked in the government support, they actually started to leverage it and attract even more private funds, in an self-feeding loop that created today’s monster-bubble.

Very few people know they even got money from BARDA and DARPA. As in “military funds”.

Remember this lie from earlier?
“The company has been funded over the years by billions of dollars of private investment,” Zaks told the Freakonomics podcast in August. “Those billions created the opportunity for the U.S. government to come in earlier this year and say, ‘I’m going to add some money to the pot to make sure that you get the development for this vaccine right.'”
Watch this claim getting nuked:

Taken from:

This grid above looks familiar to you? It does to me, but it’s not blood from people who underwent Covid genetic therapies, just something similar. Taken from:

KEI asks DOD to investigate failure to disclose DARPA funding in Moderna patents

  by  Knowledge Ecology International (KEI)

Luis Gil Abinader has taken a deep dive into Moderna’s surprising practice of never declaring government funding in its 126 patents and 154 patent applications, despite having had funding from multiple federal agencies.

One outcome of his research is a 25 page report (RN-2020-3) on Moderna’s failure to report funding from DARPA, and a request by KEI to DOD and DARPA to remedy this, including by taking title to patents where disclosures should have been made. (Text of letter below, and PDF version here).

KEI will also send a letter to BARDA. The letter below was addressed to DOD and DARPA, and focuses on their funding.

Context

The obligation to disclose federal funding in patent applications has been subject to presidential executive orders, statutes, regulations and contracts, including those cited and quoted in Abinader’s report. The disclosure clarifies the public’s rights in the inventions and the obligations on the entity getting the money, on everything from the government’s worldwide royalty free license to the public’s march-in rights, obligations to make inventions available to the public on reasonable terms, and additional safeguards that can be exercised by a government inclined to do so.

Secondly, the disclosure changes the narrative about who has financed the inventive activity, often the most risky part of development.

One of the earlier norms on this was Franklin Roosevelt’s Executive Order 9424, on the Establishment of a Register of Government interests in patents.

In 2018, the regulations on disclosure were modified by NIST (see 83 FR 15954), where, among other things, the government gave itself unlimited time to remedy a failure to disclose federal funding, to eliminate one loophole that created an incentive ignore the disclosure requirement.

In the past, the US Department of Defense has taken title to patents where federal funding was not disclosed. See: Campbell Plastics v. Brownlee, 389 F.3d 1243 (Fed. Cir. 2004).

There is more on the broader issue of disclosure of government funding in patents here: https://www.keionline.org/bayh-dole/failure-to-disclose

The research on the Moderna/DARPA funding is outlined in a 25 page August 27, 2020 report by Luis Gil Abinader, titled: “Moderna failures to disclose DARPA funding in patented inventions.” RN-2020-3

Below is the text of the KEI letter to Dr. Mark T. Esper, Secretary of Defense, and Dr. Amy Jenkins, of the Pandemic Prevention Platform for the Defense Advanced Research Projects Agency (DARPA), regarding the apparent failure by Moderna to disclose DARPA funding in patent applications.
PDF copy here:

2020. September 18. DARPA letter to KEI confirming investigation of Moderna for failure to report government funding in patent applications. https://www.keionline.org/33970

2020. September 4. BARDA is investigating Moderna’s failures to disclose BARDA funding in patent applications. https://www.keionline.org/33907

2020. September 2. KEI request to BARDA concerning Moderna obligations to disclose federal funding in patent applications. https://www.keionline.org/33892

2020. August 30. DARPA announces investigation into Moderna’s apparent failures to disclose mRNA vaccine patents. https://www.keionline.org/33832

2020. August 28. KEI asks DOD to investigate failure to disclose DARPA funding in Moderna patents. https://www.keionline.org/33763

2020. August 27. 2020:3 KEI Research Note: Moderna failures to disclose DARPA funding in patented inventions. https://www.keionline.org/rn-2020-3

2020. August 5. BARDA Responds to KEI, Public Citizen Letter Asking BARDA to Enforce Moderna Contract. https://www.keionline.org/33633

2020. August 4. KEI and Public Citizen request BARDA to address Moderna’s noncompliance with COVID-19 vaccine contract term. https://www.keionline.org/33618

2020. July 1. KEI receives seven new contracts for COVID 19 research from BARDA and DOD, including five using “Other Transactions Authority” that weaken or eliminate Bayh-Dole and FAR Safeguards. https://www.keionline.org/covid19-ota-contracts

2020. May 21. Moderna and US Government Funding of its COVID-19 Vaccine Candidate. https://www.keionline.org/33150

MORE Press Coverage

Washington Post
2020. August 28. “Moderna failed to disclose federal support in vaccine patents, researchers say: The company with a leading coronavirus vaccine candidate did not adhere to a law designed to protect public investment.” Washington Post. Christopher Rowland.
https://www.washingtonpost.com/business/2020/08/28/moderna-vaccine-patents-darpa-funding/

Bloomberg
2020. August 29. “Moderna’s Patents Probed by U.S. Defense Department, FT Says.” Bloomberg. Chiara Vasarri. https://www.bloomberg.com/news/articles/2020-08-29/u-s-government-s-darpa-probes-patents-filed-by-moderna-ft

Axios
2020. August 5. “Moderna skirts disclosures of coronavirus vaccine costs.” Axios. Bob Herman. https://www.axios.com/moderna-barda-coronavirus-funding-disclosure-2775a517-a775-485a-a509-b6906c8535a9.html

STAT
2020. September 4. “A second U.S. agency will review if Moderna disclosed federal funding in vaccine patents.” STAT. Ed Silverman. https://www.statnews.com/pharmalot/2020/09/04/moderna-vaccine-darpa-barda-patents-covid19/

2020. August 8. “Moderna failed to disclose federal funding for vaccine patent applications, advocates say.” STAT. Ed Silverman. https://www.statnews.com/pharmalot/2020/08/28/moderna-covid19-vaccine-coronavirus-patents-darpa/

2020. August 4. “BARDA faces pressure to force Moderna to disclose cost details from its Covid-19 contract.” Ed Silverman. https://www.statnews.com/pharmalot/2020/08/04/covid19-coronavirus-pandemic-barda-moderna-vaccine-transparency/

Financial Times
2020. August 29. “US government’s Darpa probes Moderna’s vaccine patents: Researchers accuse biotech company of failing to disclose federal grants in patents which also cover Covid-19 candidate.” Financial Times. Donato Paolo Mancini. https://www.ft.com/content/2be1f87e-9e96-4e23-9cc5-33ba35e50586

National Public Radio (NPR)
2020. August 4. “Prices For COVID-19 Vaccines Are Starting To Come Into Focus.” NPR. Sydney Lupkin. https://www.statnews.com/pharmalot/2020/08/04/covid19-coronavirus-pandemic-barda-moderna-vaccine-transparency/

Health Policy Watch
2020. September 3. “US Biomedical Advanced Research & Development Agency Reviews Moderna’s US Patents For Alleged Failure To Disclose Federal Funding.” Health Policy Watch. Grace Ren.
https://healthpolicy-watch.news/pharma-watchdog-requests-further-inquiries-into-modernas-us-patents/

2020. September 1. “US Department Of Defense Is Investigating Moderna’s Patents For Allegedly Failing To Disclose Federal Support.” Health Policy Watch. Grace Ren. https://healthpolicy-watch.news/usagency-investigating-moderna-for-allegedly/

The Pharma Letter
2020. September 4. “Non-profit says Moderna hid federal funding from patent office.” The Pharma Letter. https://www.thepharmaletter.com/article/nonprofit-says-moderna-hid-federal-funding-from-patent-office

Life Sciences Intellectual Property Review
2020. September 8. “Moderna’s COVID-19 and Zika patent applications to be investigated.” Life Sciences Intellectual Property Review. Muireann Bolger. https://www.lifesciencesipreview.com/news/moderna-s-covid-19-and-zika-patent-applications-to-be-investigated-4183

Law360
2020. September 4. “HHS Unit Probes Funding For Moderna’s Patented Vaccines.” Law360. Kevin Stawicki. https://www.law360.com/articles/1307690/hhs-unit-probes-funding-for-moderna-s-patented-vaccines

2020. August 31. “DOD Investigating Moderna’s Vaccine Patents.” Law360. Kevin Stawicki. https://www.law360.com/compliance/articles/1305849/dod-investigating-moderna-s-vaccine-patents

2020. August 28. “Activists Say Moderna Hid Gov’t Support For Vaccine Patents.” Law360. Kevin Stawicki. https://www.law360.com/articles/1305474

Moderna’s vaccine was developed with support from the NIAID, and, as covered in a past fact check, analysis from Axios found that the National Institutes of Health, of which the NIAID is part, may own intellectual property used in producing Moderna’s vaccine. Dr. Francis Collins, director of NIH, has also said that NIH has a stake in intellectual property used in the vaccine, though what exactly this means in practical terms is unclear. 

The Dispatch Fact-check

Also…

All the documents Glenn Beck is creaming about and more can be found below:

Nipah virus as in…?

READ: URGENT! DEBUNKING THE NEXT ENGINEERED PANDEMIC: HEMORRHAGIC FEVER (NIPAH, MARBURG, EBOLA)

Well, yeah, no coincidence here either, more proof to that below.

SO WE HAVE A FINACIER WHO TOOK OVER A WELL FUNDED PHARMA START-UP AND BROUGHT IN HUGE FUNDS, IGNITING THE MOTHER OF ALL ENRONS. WHO’S THIS GUY?!

Buckle up, friends, this so far was jus the prelude.

Bancel came to Moderna from the French Merieux Institute.

Merieux happens to be the French billionaire who helped China build the infamous P4 Lab in Wuhan.

Merieux also happens to be an old friend of Xi’s.

That Xi visit at the Merieux HQ in France happened in 2014, not long after this:

Obama & Xi working together on a pandemic playbook in 2012

And then, in 2018..

2017

Bancel maintained a top role in the Merieux Foundation long after leaving the BioMerieux division for Moderna.

CA Merieux Foundation

Therefore no surprise that Moderna was allegedly the first to get the SARS-COV2 genetic code and start working on the mRNA injection.

CONFIDENTIAL DOCUMENTS: MODERNA SENT A MRNA CORONAVIRUS VACCINE CANDIDATE TO UNIVERSITIES WEEKS BEFORE EMERGENCE OF COVID-19

MORE COINCIDENCE THEORIES

In 2017, Moncef Slaoui, the brain behind GSK, also took a seat on the board of Moderna,

Trump awarded Moderna almost $0.5Billion from public money a few days before nominating Slaoui as Warp Speed co-chief. in May 2020.

Trump’s Moroccan “vaccine czar”: worked for Bill Gates, Google, GSK. Worked in China. Transhumanist. Lockdown fanatic

“Valera’s efforts (Moderna subsidiary) have resulted in the demonstration of preclinical efficacy of Moderna’s mRNA-based vaccines in multiple viral disease models, Moderna said.

In the partnership with the Gates Foundation, Valera will apply its mRNA vaccine platform as well as Moderna’s drug platform Messenger RNA Therapeutics™. Designed to produces human proteins, antibodies, and entirely novel protein constructs inside patient cells, the therapeutics are secreted or active intracellularly.” – Genetic Engineering & Biotechnology News

To avoid a conflict of interest, Slaoui resigned from the board of the Massachusetts-based biotech firm Moderna, which had been developing a vaccine for the coronavirus.
He stepped down but he didn’t give up his stakes in Moderna, as the Daily Beast reports:

“Slaoui’s ownership of 156,000 Moderna stock options, disclosed in required federal financial filings, sparked concerns about a conflict of interest.
Democratic Massachusetts Senator Elizabeth Warren called Slaoui out over the matter on Twitter: “It is a huge conflict of interest for the White House’s new vaccine czar to own $10 million of stock in a company receiving government funding to develop a COVID-19 vaccine. Dr. Slaoui should divest immediately.”
The company’s shares skyrocketed last month after news broke of the $483 million in federal funding to work on a coronavirus vaccine.
Slaoui could not immediately be reached for comment on the matter.”

Slaoui also sits on the boards of SutroVax, the Biotechnology Innovation Organization, the International AIDS Vaccine Initiative, and the PhRMA Foundation

Gates, Fauci and Slaoui have long been making and selling scandalous vaccines together. It’s a cartel

So we should add Bancel to this cover graphic
DAVOS 2022: BANCEL AND FAUCI MEET AGAIN TO WHINE ABOUT THE ANNOYANCE WE ARE TO THEM. MORE TO COME, SCUMBAGS!

LAST MINUTE:

The circle has just closed.
Unless China faked another interview to prop up another myth.

So this has never been about health, just a global scale racketeering operation that’s coming to light about about to go bust. You can speed up this process simply by spreading this expose far and wide!

UPDATE MARCH 21, 2022: VOILA!

Via our ex-BlackRock friend Edward Dowd. I rest my case, but I bet they will “unrest” it soon.

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

ORDER

THERE’S NO BETTER PREVENTION THAN SHARING THE KNOWLEDGE FASTER THAN THEY SHARE THEIR PROPAGANDA!

The original title of this article was URGENT! DEBUNKING THE NEXT ENGINEERED PANDEMIC: NIPAH VIRUS. I expanded the scope because in the meantime I learned they are ramping up propaganda for all three. These viruses have more things in common, as you will find out below.

You should actually begin with this earlier report:

‘OBSCENE’ PANDEMIC BONDS ISSUED IN 2017 BY WORLD BANK FOR CORONAVIRUSES, MARBURG, EBOLA. DESIGNED TO FAIL

UPDATE 7, JAN 10 2022: Dr. Robert Malone Warns Of ‘Ebola-Like Hemorrhagic Fever’ Super Virus In China Caused By Mutations Due To Mass Vaccination

UPDATE 6: NOVEMBER 9, 2021:

To further develop the ChAd3 Ebola and Marburg vaccines, Sabin has entered into a Research Collaboration Agreement with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases.
The Sabin Vaccine Institute, a non-profit organization founded in 1993, is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Sabin received more than $110 million for vaccine R&D programs from public and philanthropic funding sources, including the Bill & Melinda Gates Foundation, European Commission, Dutch Ministry of Foreign Affairs, Global Health Innovative Technology Fund and the Michelson Medical Research Foundation.

SABIN VACCINE INSTITUTE, August 6, 2019

Washington DC, Oct. 21, 2021 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute (Sabin) announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has exercised the third contract option, valued at $34.5 million, under the 2019 contract to advance the development of vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials.  

In September 2019, BARDA awarded Sabin a development contract, valued up to $128 million, and has already provided funding of $40.5 million. This third contract option will enable continued nonclinical efficacy and safety studies, Phase 2 clinical trials in Africa, and vaccine manufacturing processes to ensure quality and safety.

In August, a case of Marburg disease was confirmed in the West African country of Guinea where the Ministry of Health officially declared an outbreak of Marburg.1 This recent case, as well as Marburg’s history of outbreaks and their potential for future devastating outbreaks, demonstrates that preventative measures are overdue to protect civilian populations, military personnel, first responders, health care workers and laboratory workers, both in the United States and abroad, against these emerging infectious diseases.

Ebola Sudan and Marburg viruses are closely related to Ebola Zaire virus, which has caused more than 2,200 deaths since 2018, leading the World Health Organization (WHO) to declare it a Public Health Emergency of International Concern. Like Ebola Zaire, Ebola Sudan and Marburg are among the world’s deadliest viruses, causing hemorrhagic fever with subsequent death in an average of 50 percent of cases.2,3

“Even as the world struggles with the COVID-19 pandemic, disease caused by Ebola Sudan and Marburg viruses continue to be a serious threat, as we have seen with the recent outbreak of Marburg in Guinea. We are grateful for BARDA’s continued support of Sabin’s efforts to advance vaccines against these deadly viruses,” said Sabin Chief Executive Officer Amy Finan. “We also thank our partners at the Vaccine Research Center of the NIH National Institute of Allergy and Infectious Diseases for their continued collaboration, and GSK for their earlier work on the candidates.” 

The two candidate vaccines, based on GSK’s proprietary ChAd3 platform, were exclusively licensed to the Sabin Vaccine Institute from GSK in 2019.

This project has been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50119C00055.

Learn more about Sabin’s Ebola Sudan and Marburg program.

This above is the official Sabin Inst. press release, this below isn’t:

November 4, 2021 – The U.S. CDC published a Level Three Travel Advisory for the recent Ebola outbreak in the Beni Health Zone of the Democratic Republic of the Congo.

November 3, 2021 – The U.S. CDC vaccine advisory committee reviewed previous recommendation preexposure vaccination with Ervebo for adults aged ≥18 years in the U.S. population who are at highest risk for potential occupational exposure to Ebola virus species Zaire ebolavirus because they are: responding to an outbreak of Ebola Virus Disease (EVD), or work as health care personnel at federally designated Ebola treatment centers in the U.S., or work as laboratorians or other staff at biosafety level 4 facilities in the U.S.

November 2, 2021 – The WHO reported additional cases and deaths confirmed in the Ebola virus disease outbreak in the Democratic Republic of the Congo with two new health areas affected. A total of 394 people (67 primary care providers including nine high-risk contacts, nine contacts of contacts, and 49 probable contacts) have been vaccinated including 182 contacts of contacts, 125 probable contacts, and 87 high-risk contacts.

October 29, 2021 – A Research Article – Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomized, placebo-controlled Phase II clinical trial in Africa – was published by the journal PLOS Medicine. Conclusion – The Ad26.ZEBOV and MVA-BN-Filo combo vaccination were well tolerated and immunogenic in healthy and HIV-infected African adults. Increasing the interval between vaccinations from 28 to 56 days improved the magnitude of humoral immune responses. Antibody levels persisted to at least 1 year, and an Ad26.ZEBOV booster vaccination demonstrated the presence of vaccination-induced immune memory. These data supported the approval by the European Union for prophylaxis against EBOV disease in adults and children ≥1 year of age.

October 27, 2021 – IAVI announced an award of up to US$126 million from the Biomedical Advanced Research and Development Authority to develop two recombinant vesicular stomatitis virus (rVSV)-vectored filovirus vaccine candidates. This award supports preclinical activities and includes options for clinical development up to and inclusive of a Phase II clinical trial of IAVI’s rVSV Sudan ebolavirus vaccine candidate (rVSVΔG-SUDV-GP). Optional work that would continue the development of IAVI’s Marburg virus vaccine candidate (rVSVΔG-MARV-GP) that is currently supported by the Defense Threat Reduction Agency of the U.S. Department of Defense could be funded at a later date.

“Vectored” means, most likely, mRNA or some other genetic / nanotech targeting technology.

October 20, 2021 – The WHO African Region reported 5 Ebola cases, and over 27,000 travelers have been screened in the DRC. Furthermore, over 116 people have been vaccinated.

October 17, 2021 – Africa News reported Ebola vaccinations started in Beni, DRC, after at least two people died due to the virus in October 2021. The WHO African Region Tweeted DRC Situation Report (17/10/21) 5 confirmed cases, three deaths, 369 contacts identified, and 308 contacts monitored.

October 13, 2021 – Democratic Republic of the Congo (DRC) health officials confirmed an Ebola vaccination campaign had launched in the North Kivu province where one confirmed Ebola case, plus three related suspected deaths, were recently reported. About 1,000 doses of the rVSV-ZEBOV Ebola vaccine and other medical supplies were delivered from the capital Kinshasa to Goma city in North Kivu. The DRC has more than 12,000 vaccine doses in Kinshasa that can be deployed if necessary.

October 10, 2021 – The WHO reported additional Ebola cases related to the recent DRC case of a 3-year-old boy. A cluster of three deaths (two children and their father) who were neighbors of the case. These three patients died on 14, 19, and 29 September 2021 after developing symptoms consistent with Ebola. However, none were tested for the virus. As of October 9th, a total of 148 contacts have been identified and are under follow-up by the local response team.

October 8, 2021 – A case of Ebola has been confirmed in the eastern Democratic Republic of the Congo, five months after the end of the most recent Ebola outbreak there. The child died on October 6th. It was not immediately known if the Ebola case was related to the 2018-20 outbreak that killed more than 2,200 people in eastern Congo or the flare-up that killed six people in 2021.

September 13, 2021 – A new study based in Sierra Leone concluded the Ebola vaccine regimen from Janssen – J&J. It was found well tolerated with no safety concerns in children aged 1–17 years and induced robust humoral immune responses, suggesting the suitability of this regimen for Ebola virus disease prevention in children.

August 31, 2021 – The government of Cote d’Ivoire has informed the WHO that a second laboratory has tested samples from a patient suspected of having Ebola and has found no evidence of the virus. Around a dozen WHO experts were mobilized to support the country’s efforts, and 5,000 Ebola vaccine doses which WHO had helped Guinea procure were sent from Guinea to Cote d’Ivoire.

August 23, 2021 – The WHO African region reported Ebola booster dose vaccinations in Sierra Leone following administration of the prime dose of the Johnson & Johnson Ebola vaccine in May 2021. Frontline health workers, practitioners of traditional medicines or traditional healers, and commercial motorbike riders who received the first dose are now given their second jab to maximize their protection against the disease. 

August 17, 2021 – The WHO confirmed Cote d’Ivoire deployed 2,000 vaccine doses from Merck and around 3,000 vaccine doses manufactured by Johnson & Johnson – Janssen.

August 14, 2021 – The WHO Africa reported the Ministry of Health of Cote d’Ivoire today confirmed the country’s first case of Ebola since 1994. This came after the Institut Pasteur in Cote d’Ivoire confirmed the Ebola Virus Disease in samples collected from a patient hospitalized in Abidjan’s commercial capital after arriving from Guinea.

August 9, 2021 – The WHO confirmed ‘Marburg virus disease (MVD) is a highly virulent, epidemic-prone disease associated with high case fatality rates (CFR 24-90%). In the early course of the disease, the clinical diagnosis of MVD is difficult to distinguish from other tropical febrile illnesses because of the similarities in the clinical symptoms. Differential diagnoses to be excluded include Ebola virus disease, as well as malaria, typhoid fever, leptospirosis, rickettsial infection, and plague.’

June 15, 2021 – The Southwest National Primate Research Center at Texas Biomedical Research Institute (Texas Biomed) has been awarded more than $37 million from the U.S. National Institutes of Health to continue operations into 2026. The P51 grant, given by the NIH Office of Research Infrastructure Programs, provides essential funding to house and care for nearly 2,500 non-human primates that are part of life-science research programs at Texas Biomed and partners around the globe.

June 4, 2021 – Johnson & Johnson welcomed a new recommendation by the Strategic Advisory Group of Experts on Immunization for the WHO that supports the use of the Johnson & Johnson Ebola vaccine regimen both during outbreaks for individuals at some risk of Ebola exposure and preventively, in the absence of an outbreak, for national and international first responders in neighboring areas or countries where an outbreak might spread.

June 4, 2021 – J&J confirmed about 235,000 people had received at least the first dose of the Janssen two-dose Ebola vaccine regimen.

April 10, 2021 – The government of Sierra Leone and the WHO announced Johnson & Johnson had donated about 4,500 Zabdeno and Mvabea Ebola vaccines to Sierra Leone to help prevent any Ebola outbreak. The last Ebola outbreak in Sierra Leone was in 2016.

March 25, 2021 – Ohio Gov. Mike DeWine revealed health officials are monitoring 44 people who have returned from areas of Africa with active outbreaks of Ebola.

March 25, 2021 – Oregon public health officials announced they are monitoring four people who recently visited the West African countries of Guinea and the Democratic Republic of the Congo. Regions in each of these countries are currently experiencing outbreaks of Ebola virus disease. The Oregon Health Authority and local public health departments have been in contact with these individuals, considered “persons under monitoring” since they arrived in the state earlier in March 2021.

March 23, 2021 – The WHO African Region Tweeted Guinea Ebola outbreak Situation Report (22/03/21) 18 cases, nine deaths, 78 contacts, 82% monitored. And 3,905 people have been vaccinated.

March 13, 2021 – After a request from the Guinean authorities, Russia is considering supplying a domestic vaccine against the Ebola virus to the African country, reported TASS.

May 13, 2020 – BARDA Provides the Sabin Vaccine Institute with an Additional $20 Million for Further Development of Ebola Sudan and Marburg Vaccines

The Sabin Vaccine Institute (Sabin) and its partner ReiThera Srl today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has exercised the first two options, valued at $20 million, under the 2019 contract to advance the development of vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials. In September 2019, BARDA awarded Sabin a development contract, valued at $128 million, and provided the initial funding award of $20.5 million. This second $20 million award will enable the manufacture and release of clinical vaccine material developed by ReiThera, a specialist in the development and cGMP manufacture of adenoviral vector vaccines. The funding will also support non-clinical studies to evaluate efficacy and immune response.

UPDATE 5: NOVEMBER 7, 2021: MARBURG GOES VIRAL ON INTERNET ONLY, YET. I’m happy awareness increases, it’s crucial. I’ve addressed this virus below, but not many had the patience to go through all text, and I kind of understand them, but there’s no easier way than reading.
Here’s another angle to keep in sight when computing all this info:

UPDATE 4: OCTOBER 19 2021: THE FEARPORN CAMPAIGN TAKES SPEED AS IF THEY ARE TO RELEASE THIS SOON. IF YOU FALL FOR THEIR BRAINWASH, THEY HAVE NO REASON TO STOP.

And they’re still not running out of stupid ideas we can see through:

UPDATE 3: OCTOBER 17 2021:

TOLD YA!

Guess who has a vaccine in works for it

Oh, look who pushes the fear! Exactly who I would’ve expected:

Later update: In the meantime I’ve learned that Marburg (an Ebola relative) and Xinjiang fever, a Chinese relative of the Yellow Fever virus, are also top candidates, and that goes in line with the Fauci e-mails I highlighted below. I will be back with more details shortly. Almost certainly it will be some form of hemorrhagic fever, most likely to cover for injections side-effects on the blood stream.

UPDATE 2:

One month later, they’re starting to catch up and it’s still not too late to un-play it if this goes BOOM NOW!



By the end of last century, The Military has abandoned you and has joined Pharmafia and the super-rich elites in a plan to govern you with bioweapons and psy-ops. As I’ve said many times, Big Pharma and Big Tech are long gone, The Military BioTech Complex has been running the show for quite a while.
This is just a chapter from that book, more to come if we get some love.

WHAT YOU NEED TO KNOW:

INDIA BLACKLISTED US CDC FOR SECRETLY FUNDING BIOWEAPONS RESEARCH IN MANIPAL – Silview.media

Government pulls up U.S. agency for work on Nipah virus – The Hindu

NIPAH IS ONE OF THREE VIRUSES MODIFIED BY WUHAN LAB AT NIAD’S REQUEST, FAUCI E-MAIL REVEAL – Silview.media

SOURCE

Canadian lab’s shipment of Ebola, Henipah viruses to China raises questions

  • Henipah and Nipah are interchangeable

Scientists at the National Microbiology Lab sent live Ebola and Henipah viruses to Beijing on an Air Canada flight March 31, and while the Public Health Agency of Canada says all federal policies were followed, there are questions about whether that shipment is part of an ongoing RCMP investigation.

Ebola and Henipah are Level 4 pathogens, meaning they’re some of the deadliest viruses in the world. They must be contained in a lab with the highest level of biosafety control, such as the one in Winnipeg. 

Two months after that shipment, on May 24, the Public Health Agency of Canada (PHAC) referred an “administrative matter” to RCMP that resulted in the removal of two Chinese research scientists — Xiangguo Qiu and Keding Cheng — and several international students on July 5. 

Both agencies have said repeatedly that public safety has not been at risk. 

PHAC will not confirm if the March 31 shipment is part of the RCMP investigation.

Strict protocols

Several sources, who have asked to remain anonymous because they fear for their jobs, say the pathogens may have been shipped to the Chinese Academy of Sciences in a way that circumvented the lab’s operating procedures, and without a document protecting Canada’s intellectual property rights.

Researchers working at the National Microbiology Lab on cutting-edge, high-containment research are not allowed to send anything to other countries or labs without the intellectual property office negotiating and having a material transfer agreement in place, in case the material sent leads to a notable discovery.

A PHAC spokesperson did not confirm if this shipment included such an agreement.

However, Eric Morrissette said it’s “routine” for the lab to share samples of pathogens and toxins with partners in other countries to advance scientific work worldwide.

The transfers follow strict protocols, including requirements under the Human Pathogens and Toxins Act(HPTA), the Transportation of Dangerous Goods Act, theCanadian Biosafety Standard and the lab’s standard operating procedures, Morrisette added.

“All transfers of Risk Group 4 samples follow strict transportation requirements and are authorized by senior officials at the lab and the NML tracks and keeps electronic records of all shipments of samples in accordance with the HPTA. Agreements for the transfer of materials are determined on a case-by-case basis,” Morrisette wrote in an email statement.

“On the specific shipments to China earlier this year, we can confirm that we have all records pertaining to the shipment, and that all protocols were followed as directed by the above Acts and Standards.”

Sources say Xiangguo Qiu and her husband, Keding Cheng, were escorted from the National Microbiology Lab in Winnipeg on July 5. (Governor General’s Innovation Awards)

Xiangguo Qiu is head of the National Microbiology Lab’s Vaccine Development and Antiviral Therapies section in the Special Pathogens Program. She is responsible for the lab that works with Ebola. Her husband, Keding Cheng, is also a PHAC biologist. 

After their security clearance was revoked and they were escorted from the lab, the University of Manitoba also cut ties with them and re-assigned Qiu’s graduate students, pending the RCMP investigation. No charges have been laid.

Neither scientist has responded to requests for comment, although some of their former colleagues say Qiu is not just a world-renowned scientist who helped develop a treatment for Ebola, but also a researcher with ethics and integrity.

Case raises questions 

One question raised by this case is that of intellectual property protection, says Leah West, who practises, studies and publishes in the field of national security law and lectures at the Norman Paterson School of International Affairs.

“If China was leveraging these scientists in Canada to gain access to a potentially valuable pathogen or to elements of a virus without having to license the patent  … it makes sense with the idea of China trying to gain access to valuable IP without paying for it,” she said.

Leah West says she hopes the lab and Health Canada are doing an investigation in addition to the one the RCMP is conducting. (Submitted by Leah West)

West accepts PHAC’s assertion that public safety is not an issue, even though the viruses were transported on a commercial Air Canada flight.

However, she says the fact the RCMP is involved means there’s a legitimate concern.

“You don’t send a policy breach, a bureaucratic policy breach, to the RCMP to investigate unless you believe that that policy breach has resulted in a criminal offence or could have resulted in a criminal offence. So what is the criminal offence potentially here?” West said.

She said she hopes the lab and Health Canada are also doing an internal investigation.

“I think there will need to be an inquiry into the scientists to potentially see whether or not they were compromised or any elements of their work were compromised and that China gained illegal or improper access to Canadian intellectual property … to see what China may have gained access to without knowledge, prior to this incident,” West says.

Don’t ‘jump into any conclusions too quickly’

However, the deputy director of the University of Alberta’s China Institute is urging caution when it comes to making assumptions. 

Jia Wang doesn’t dispute China has been involved in the past in espionage and intellectual property theft, but she says that country is making big investments in developing STEM (science, technology, engineering and mathematics) scholars and then putting that into innovation.

China has its own reasons to protect intellectual property because many new ideas are coming from there, Wang says.

She’s waiting to see what comes of the RCMP investigation of the lab in Winnipeg.

“As China observers, we’d like to perhaps gently remind people not to jump into any conclusions too quickly,” she said.

“It will be good to get to the bottom of this and see what might have gone wrong and what was the oversight and how can the procedures be improved or people involved can be reminded of how to adhere to the policies better.”

Jia Wang, deputy director of the University of Alberta’s China Institute, is advising caution about making assumptions concerning the case. (Submitted by Jia Wang)

The shipment of the viruses took place at a time when relations between Canada and China have been strained over the arrest of a Huawei executive, at the request of the United States. 

In retaliation, China has detained two Canadians and is boycotting Canadian canola and pork.

Because of the strained relationship between the two countries, and this case at the lab, Chinese-Canadian researchers and academics are starting to worry they may be singled out and targeted, Wang said.

“Certain assumptions are made or their loyalty to Canada is questioned in any way. And as multicultural as we are in Canada, we don’t want to see that.”  – CBC, 2019

SOURCE

On December 19, 2019, the U.S. Food and Drug Administration announced the approval of Ervebo to prevent EVD caused by Zaire ebolavirus in individuals 18 years of age and older. This report, published by the U.S. CDC on January 8, 2021, summarizes the Advisory Committee on Immunization Practices (ACIP) recommendations for using the rVSVΔG-ZEBOV-GP Ebola vaccine (Ervebo) in the USA.

On July 1, 2020, the European Medicines Agency granted Johnson & Johnson Janssen’s Zabdeno and Mvabea Ebola vaccine therapy, a prime-boost vaccination approach for preventing infectious diseases. Janssen’s Ebola vaccine regimen is specifically designed to induce long-term immunity against the Ebola virus in adults and children aged one year and above.

CanSino Biologics’s Ad5-EBOV Ebola vaccine received approval in China in October 2017. Ad5-EBOV is an adenovirus type 5 vector-based Ebola virus disease vaccine that protects against Ebola by relying on the recombinant replication-defective human adenovirus type-5 vector immune response. In addition, Ad5-EBOV is manufactured as a lyophilized powder, highly stable, and does not require storage at ultra-low temperatures. This feature renders it viable for use in resource-limited tropical areas.

The WHO published the revised Ebola Vaccine FAQ on January 11, 2020.

In 2019, World’s deadliest viruses were ‘shipped to Wuhan ‘leak lab’ from Canada by rogue scientists linked to Chinese military’ – The Sun

Experts Say Nipah Virus Has Potential To Be Another Pandemic — With A Higher Death Toll – Yahoo

What is Henipavirus?

Henipaviruses belong to the family of paramyxoviruses. Two species have been identified to be zoonotic, causing disease in animals. These are the Hendra virus (HeV) and the Nipah virus (NiV). They produce severe and often fatal illness in humans and horses.

News-Medical.net

THAT IS TO SAY ‘NIPAH’, ‘HENIPAH’ AND ‘HENIPAVIRUS’ ARE INTERCHANGEABLE HERE

Samples from early Wuhan COVID-19 patients show the presence of genetically modified Henipah virus, an American scientist has found.

Henipah was one of the two types of viruses sent to China by Chinese-born scientists from a Canadian laboratory at the centre of a controversy over the firing of the scientists and collaboration with Chinese military researchers. It is not clear whether the virus found in the Chinese samples is related to the samples sent by the Canadian lab, which were shipped in late March 2019.

The finding was confirmed for The Epoch Times by another qualified scientist.

The evidence was first found by Dr. Steven Quay, a Seattle-based physician-scientist and former faculty member at the Stanford University School of Medicine, who looked at early COVID-19 samples uploaded by scientists at the Wuhan Institute of Virology (WIV) shortly after China informed the World Health Organization about the SARS-CoV-2 outbreak.

Epoch Times Photo
Chinese virologist Shi Zhengli is seen inside the P4 laboratory in Wuhan, China, on Feb. 23, 2017. (Johannes Eisele/AFP via Getty Images)

The samples from the patients, who reportedly were found to have the “unknown pneumonia” in December 2019, were uploaded to the genetic sequence database, GenBank, on the website of the U.S. National Institute of Health (NIH).

Quay says that while other scientists around the world were mostly interested in examining the genome of SARS-CoV-2 in the samples uploaded by the WIV scientists, he wanted to see what else was in the samples collected from the patients.

So he collaborated with a few other scientists to analyze sequences from the samples.

“We started fishing inside for weird things,” Quay told The Epoch Times.

What they found, he says, are the results of what could likely be contamination from different experiments in the lab making their way into the samples, as well as evidence of Henipah virus.

“We found genetic manipulation of the Nipah virus, which is more lethal than Ebola.” Nipah is a type of Henipah virus.

The Epoch Times asked Joe Wang, PhD, who formerly spearheaded a vaccine development program for SARS in Canada with one of the world’s leading pharmaceutical companies, to verify the finding. Wang is currently the president of NTD Television Canada, the sister company of The Epoch Times in Canada.

After examining the evidence, Wang said he was able to replicate Quay’s findings on the Henipah virus. He explains that the genetic manipulation of the virus was likely for the purposes of vaccine development.

Winnipeg Lab

The firing of Chinese-born scientist Xiangguo Qiu and her husband, Keding Cheng, from the National Microbiology laboratory (NML) in Winnipeg has been the subject of much controversy in Canada, with opposition parties pressing the government for more details on the case, and the government refusing to release information citing national security and privacy concerns.

Qiu and Cheng along with several Chinese students were escorted out of NML, Canada’s only Level 4 lab, in July 2019, amid a police investigation. The two scientists were formally fired in January 2021.

The Public Health Agency of Canada (PHAC), which is in charge of NML, said the termination was the result of an “administrative matter” and “possible breaches of security protocols,” but has declined to provide further details, citing security and privacy concerns.

Epoch Times Photo
House Speaker Anthony Rota admonishes Public Health Agency of Canada President Iain Stewart in the House of Commons on June 21, 2021, for failing to provide documents related to the firing of two scientists from the National Microbiology Laboratory in Winnipeg. (The Canadian Press/Sean Kilpatrick)

During her time at NML, Qiu travelled several times in an official capacity to WIV, helping train personnel on Level 4 safety. The Globe and Mail later reported that scientists at NML have been collaborating with Chinese military researchers on deadly pathogens, and that one of the Chinese military researchers worked at the high-security Winnipeg lab for a period of time.

Documents and emails released by PHAC show that the shipment of Henipah and Ebola samples was done with the permission of NML authorities.

In one of the emails sent in September 2018, David Safronetz, chief of special pathogens at PHAC, informs then-head of NML Matthew Gilmour and other lab administrators about the request from WIV for the shipment of the samples, saying “I trust the lab.”

In response, Gilmour asks about the nature of the work that will be done at the Wuhan lab, and why the lab doesn’t get the material from “other, more local labs.” He also tells Safronetz that it’s “good to know that you trust this group,” asking how NML was connected with them.

In his reply, Safronetz doesn’t specifically say what the samples will be used for in China, but notes they will only be sent once all paperwork and certification is completed. He also says the WIV is requesting the material from NML “due to collaboration” with Qiu.

He adds, “Historically, it’s also been easier to obtain material from us as opposed to US labs. I don’t think other, closer labs have the ability to ship these materials.”

Gilmour resigned from his position at NML in May 2020 and joined a UK-based bioresearch company.

MPs have asked NML management why shipment of the samples was allowed and whether they knew if China performs any Gain of Function (GoF) research at WIV. GoF research involves increasing the lethal level (virulence) or transmissibility of pathogens.

NML’s acting scientific director general Guillaume Poliquin told MPs during a parliamentary committee meeting on March 22 that the lab only sent the samples to WIV after receiving assurance that no GoF research would take place.

Conservative MP John Williamson pressed for more answers, saying the word of the state-run Chinese lab can’t be trusted as the Chinese regime “has a history of theft and lies.”

The issue of GoF research at WIV has been a point of contention in the United States between lawmakers and Dr. Anthony Fauci, NIH’s head of the National Institute of Allergy and Infectious Diseases, whose organization has funded research (through EcoHealth Alliance) on coronaviruses at the Wuhan lab. U.S. Sen. Rand Paul says published work from WIV on coronaviruses shows the lab is conducting GoF research, a charge Fauci denies.

Epoch Times Photo
The P4 laboratory on the campus of the Wuhan Institute of Virology in Wuhan, China, on May 13, 2020. (Hector Retamal/AFP via Getty Images)

The Epoch Times sought comment from PHAC, including as to how the agency addressed issues of intellectual property and the development of any products such as vaccines with WIV, but didn’t hear back by time of publication.

Despite repeated requests by opposition parties for more details related to the firing of the two NML scientists, the Liberal government has refused to provide records, saying there are national security and privacy concerns.

After the House of Commons issued an order for the government to disclose the information, the government took the Speaker of the House to court to obtain confirmation from a judge that it can withhold the documents. The government later dropped its court case once Prime Minister Justin Trudeau called an election and Parliament was dissolved. – Epoch Times

LATER UPDATE: JUST LEARNED NIPAH WAS THE INSPIRATION FOR ANOTHER DRILL VERY SIMILAR TO EVENT201 – CLADE-X

NOTEWORTHY: Germany is the epicenter of this psyop, in their scenario

‘For the next pandemic, we’ll have gigantic mRNA factories in India’ – Bill Gates

The next pandemic: Nipah virus? – Bill Gates’ GAVI

SOURCE

Oh, look, a Dutch NGO on Taiwan TV pushing Nipah fearporn to WHO as early as February 2021:

SOURCE

India fighting to contain Nipah, a virus deadlier than COVID-19 – NY Post

Experimental drug by Gilead completely effective against Nipah virus infection in monkeys – NIH

ALSO IN 2019, INDIA CONDUCTS NIPAH OUTBREAK DRILLS. OFFICIALS SAY THEY HOPE FOR FULL PREPAREDNESS BY 2022:

ECO-HEALTH ALLIANCE INVOLVED AGAIN!

Remember the host?

THERE ARE SEVERAL PATENTS FOR NIPAH DRUGS AND SOME ARE mRNA GENE THERAPIES REGISTERED AS VACCINES

SOURCE
SOURCE
SOURCE

UPDATE 3: I FOUND CREDIBLE SOURCES FOR MOST OF DR. ARYANA LOVE’S EXPLOSIVE CLAIMS BELOW:

I didn’t have an in depth look at all her sources, I can’t have a final 100% verdict, but I did more than a glance and no lies detected. You can review her blog post yourself HERE.
This might be the closure to this report and the start for another.

OBAMA: EBOLA RESPONSE A TRIAL RUN FOR A POTENTIAL AIRBORNE VIRUS THAT MIGHT HIT SOON (2014)

BONUS

This is from 2014, but the story goes a way long back. And forward. Let’s not forget Putin is a Davos regular since before he became such a literal czar.

‘Contagion’ Reality Check: CDC Experts Explore Some of the Film’s Scenarios – PBS

WE ARE BEING PRIMED FOR THE DARKEST WINTER

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

BY THE DAILY EXPOSE ON  

A confidentiality agreement shows potential coronavirus vaccine candidates were transferred from Moderna to the University of North Carolina in 2019, nineteen days prior to the emergence of the alleged Covid-19 causing virus in Wuhan, China.

The confidentially agreement which can be viewed here states that providers ‘Moderna’ alongside the ‘National Institute of Allergy and Infectious Diseases’ (NIAID) agreed to tranfer ‘mRNA coronavirus vaccine candidates’ developed and jointly-owned by NIAID and Moderna to recipients ‘The Universisty of North Carolina at Chapel Hill’ on the 12th December 2019.

Found on page 105 of the agreement

The material transfer agreement was signed the December 12th 2019 by Ralph Baric, PhD, at the University of North Carolina at Chapel Hill, and then signed by Jacqueline Quay, Director of Licensing and Innovation Support at the University of North Carolina on December 16th 2019.

Recipient signatories found on page 107

The agreement was also signed by two representatives of the NIAID, one of whom was Amy F. Petrik PhD, a technology transfer specialist who signed the agreement on December 12th 2019 at 8:05 am. The other signatory was Barney Graham MD PhD, an investigator for the NIAID, however this signature was not dated.

NIAID signatories found on page 107

The final signatories on the agreement were Sunny Himansu, Moderna’s Investigator, and Shaun Ryan, Moderna’s Deputy General Councel. Both signautres were made on December 17th 2019.

Moderna signatories found on page 108

All of these signatures were made prior to any knowledge of the alleged emergence of the novel coronavirus. It wasn’t until December 31st 2019 that the World Health Organisation (WHO) became aware of an alleged cluster of viral pneumonia cases in Wuhan, China. But even at this point they had not determined that an alleged new coronavirus was to blame, instead stating the pneumonia was of “unknown cause”.

It was not until January 9th 2020 that the WHO reported Chinese authorities had determined the outbreak was due to a novel coronavirus which later became known as SARS-CoV-2 with the alleged resultant disease dubbed COVID-19. So why was an mRNA coronavirus vaccine candidate developed by Moderna being transferred to the University of North Carolina on December 12th 2019?

The same Moderna that have had an mRNA coronavirus vaccine authorised for emergency use only in both the United Kingdom and United States to allegedly combat Covid-19.

What did Moderna know that we didn’t? In 2019 there was not any singular coronavirus posing a threat to humanity which would warrant a vaccine, and evidence suggests there hasn’t been a singular coronavirus posing a threat to humanity throughout 2020 and 2021 either.

Considering the fact a faulty PCR test has been used at a high cycle rate, hospitals have been empty in comparison to previous years, statistics show just 0.2% of those allegedly infected have died within 28 days of an alleged positive test result, the majority of those deaths by a mile have been people over the age of 85, and a mass of those deaths were caused by a drug called midazolam, which causes respiratory depression, and respiratory arrest.

Perhaps Moderna and the National Institute of Allergy and Infectious Diseases would like to explain themselves in a court of law? – THE DAILY EXPOSE 

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

Sometimes my memes are 3D. And you can own them. Or send them to someone.
You can even eat some of them.
CLICK HERE

How is this NOT on every screen like the first batch of Fauci e-mails?!?!

(Washington, DC) Judicial Watch announced on 4th of June 2021 that it obtained 280 pages of documents from the Department of Health and Human Services revealing that from 2014 to 2019, $826,277 was given to the Wuhan Institute of Virology for bat coronavirus research by the National Institute of Allergy and Infectious Diseases (NIAID), which is headed by Dr. Anthony Fauci. 

The documents, some of which were redacted or withheld in their entirely, were obtained through a Freedom of Information Act (FOIA) lawsuit seeking records of communications, contracts and agreements with the Wuhan Institute of Virology in China (Judicial Watch, Inc. v. U.S. Department of Health and Human Services (No. 1:21-cv-00696)). The agency is only processing 300 pages records per month, which means it will take until the end of November for the records to be fully reviewed and released under FOIA.

The records include a chart of NIAID funding to the Wuhan Institute of Virology sent on April 21, 2020, by NIAID’s Chase Crawford to Principal Deputy Director Hugh Auchincloss and other NIAID officials. The agency funds directed to the Wuhan Institute of Virology between the years 2014-2019 total $826,277. All of the projects listed in the chart are titled “Understanding the Risk of Bat Coronavirus Emergence.”

In an April 15, 2020 email marked “high” importance, Principal Deputy Director of NIH Lawrence Tabak emailed Fauci, NIH Director Francis Collins, and other NIH officials with the subject line: “HEADS UP: Wuhan lab research:”

Tabak: WH has strongly embraced concerns raised by Congressman Gaetz who is publicly criticizing HHS/NIH for funding the Wuhan laboratory’s bat research. Here’s this quote from another article: “I’m disgusted to learn that for years the US government has been funding dangerous and cruel animal experiments at the Wuhan Institute, which may have contributed to the global spread of coronavirus, and research at other labs in China that have virtually no oversight from US authorities.” [Emphasis in original]

This is a large multi-country study with Wuhan being one site. The principal investigator, Peter Daszak, is based in NY at EcoHealth Alliance, Inc. [Emphasis in original]

Tabak provides details of the grant to Peter Daszak, president of EcoHealth Alliance, for a project titled “Understanding the Risk of Bat Coronavirus Emergence.” Tabak continues, saying, “The 3.7M dollar figure is over 6 years to all sites which include (several in) China, Thailand, Cambodia, Laos, Vietnam, Malaysia, Indonesia and Myanmar. We estimate that approximately $826,300 has been spent at this site since the inception of the grant. Yearly costs appear to be about 80K/year. The grant is in year 6 of a total of 10 year.”

Also read: US RAN GRUESOME BIOWEAPON RESEARCH IN OVER 25 COUNTRIES. WUHAN, TIP OF AN ICEBERG. ECOHEALTH ALLIANCE IMPLICATED AGAIN

A January 9, 2020, email exchange labeled “high” importance between NIAID Senior Scientific Advisor Dr. David Morens and Daszak details the relationship between the Fauci agency and the Wuhan Institute of Virology: 

Morens: Hi guys, do any of you have any inside info on this new coronavirus that isn’t yet in the public domain? Or any thoughts? 

Daszak: Yes – lots of information and I spoke with Erik Stemmy and Alan Embry yesterday before the news was released. Erik is my program officer on our coronavirus grant specifically focused on China…. 

Morens: Thanks, the excitement never ends, right?

Daszak: NIAID has been funding coronavirus work in China for the past 5 years … (1R01Al110964: “Understanding the Risk of Bat Coronavirus Emergence” ). That’s now been renewed … Collaborators include Wuhan Institute of Virology (currently working on the nCoV), and Ralph Baric [of University of North Carolina]. 

*** 

Also-FYI, prior to the R01, we worked under an R01 with Eun-Chung Park as program officer on viral discovery in bats, where originally identified SARS-CoV as having a likely origin in bats (published in Science)….

Morens: Great info, thanks. Tony doesn’t maintain awareness of these things and doesn’t know unless program officers tell him, which they rarely do, since they are across town and may not see him more than once a year, or less…. Interested in your feeling about where this is going. The experts are buzzing around us are all over the map, between doomsday and not that big a deal, with everything in between.

On January 23, 2020, a senior NIH official Melinda Hoskins forwarded a Daily Mail article to colleagues discussing NIH/NIAID funding of the bat virus research, and noting that Fauci would be briefing senators the following morning. Hoskins says, “Would you please confirm the exact nature of our support to the Wuhan Institute of Virology/Biosafety Lab.” 

Another official, Barbara Mulach, responds that, “We’ve identified one grant with a sub-grant to Wuhan Institute of Virology (thanks for the lead) and one primary grant to Wuhan University. We are trying to get clarification whether or not the two organizations are related so we know if the second application is relevant to the request or not.”

She provides data showing a “Sub-award to Wuhan Institute of Virology,” with Daszak as principal investigator for a project titled, “Understanding the Risk of Bat Coronavirus Emergence,” and she provides information on another award, grant number R01AI119064-06, with principal investigator Ke Lan, going to Wuhan University and titled, “Versatile functions of LANA in KSHV pathogenesis.”

In an April 13, 2020, email from NIH official Emily Erbelding to NIH colleagues, Erbelding notes that the “entire amount of the new Daszak grant (year 6 funded in FY19) is about 3.64 M. The total amount that will go to Wuhan Institute of Virology under this grant will be about $750K ($76,301 had already been sent to Wuhan in year 1 according to the NOA).” Additionally, the email notes that bat sampling work done during years 2011-2015, in addition to receiving funding from Daszak’s grant, “could also have been supported by USAID Predict program (which was also funding the Wuhan lab).”

Also read: TRIPLE-BOMBSHELL ON #WUHAN: #FAUCI, #WHO AND #CCP INVOLVED IN GAIN-OF-FUNCTION RESEARCH JUST PRIOR TO “PANDEMIC”

Auchinloss forwards Erberlding’s note to Fauci, saying, “This is higher but not extraordinarily higher than I originally indicated which was for some earlier work.” Fauci replies, “Thanks.”

In an April 15, 2020, email exchange, Tabak asks his colleagues if Daszak’s team had “published anything seminal related to the current pandemic.” Erbelding responds, “Peter’s only publication on SARS CoV2 since the epidemic began is thought piece in NEJM [New England Journal of Medicine]” to which she provides a hyperlink. She adds, “Note that all of the prior work on zoonotic reservoirs of CoV’s was also supported by USAID funding through a program called PREDICT, which has since ended.”

On October 1, 2017, after receiving Daszak’s email related to his then-unpublished paper describing detailed research into a novel bat-born virus tied to Swine Acute Diarrheal Syndrome, Fauci forwards Daszak’s email and paper on to NIH official Greg Folkers, saying, “Confidential, but fyi for you.” Daszak says, “You should know that this work was supported by a NIAID ROl that [NIH’s] Erik Stemmy is the Program Officer for, and that I’m PI [principal investigator] on, with Zhengli Shi [the director of the Center for Emerging Infectious Diseases of the Wuhan Institute of Virology] as co-PI.”

Also read: LMFAO! FAUCI’S WUHAN MIDDLEMAN, PETER DAZSAK CO-AUTHORED A STUDY WITH “ANTI-VAXX GURU” ANDREW WAKEFIELD

A person whose name is redacted on April 19, 2018, CCs an email to “International Cables (HHS/OS)” with the subject line “China Virus Institute Welcomes More U.S. Cooperation on Global Health Security,” includes a U.S. cable: 

China’s Wuhan Institute of Virology, a global leader in virus research, is a key partner for the United States in protecting global health security. Its role as operator of the just-launched Biosafety Level 4 (or ‘P4’) lab- the first such lab in China – opens up even more opportunities for expert exchange, especially in light of the lab’s shortage of trained staff.

***

In the last year, the lab also hosted visits from the National Institutes of Health, National Science Foundation, and experts from the University of Texas Medical Branch in Galveston. The institute reports to the Chinese Academy of Sciences in Beijing.

P4 Lab is Open and Transparent, Officials Emphasize

 ***

Officials described the lab as a “regional node” in the global biosafety system and said it would play an emergency response role in an epidemic or pandemic. The lab’s English brochure highlighted a national security role, saying that it is “an effective measure to improve China’s availability in safeguarding national bio-safety if [a] possible biological warfare or terrorist attack happens.”

Institute officials said there would be “limited availability” for international and domestic scientists who had gone through the necessary approval process to do research at the lab. They stressed that the lab aimed to be a “worldwide, open platform” for virology. They said they welcomed U.S. Centers for Disease Control (CDC) experts, noting that the Chinese Academy of Sciences was not strong on human disease expertise, having only focused on it in the last 15 years, after the SARS outbreak. A Wuhan-based French consulate official who works on science and technology cooperation with China also emphasized that the lab, which was initiated in 2004 as a France-China joint project, was meant to be “open and transparent” to the global scientific community. “The intent was to set up a lab to international standards, and open to international research,” he said. French experts have provided guidance and biosafety training to the lab, which will continue, the French official said. Institute officials said that France provided the lab’s design and much of its technology, but that it is entirely China-funded and has been completely China-run since a “handover” ceremony in 2016. 

In addition to French assistance, experts from the NIH-supported P4 lab at the University of Texas Medical Branch in Galveston have trained Wuhan lab technicians in lab management and maintenance, institute officials said.… One Wuhan Institute of Virology researcher trained for two years at the Galveston lab, and the institute also sent one scientist to U.S. CDC headquarters in Atlanta for six months’ work on influenza.

            NIH-Supported Research Revises SARS Origin Story

NIH was a major funder, along with the National Science Foundation of China (NSFC), of SARS research by the Wuhan Institute of Virology’s [redacted.]

*** 

Ready to Help with the Global Virome Project

Institute officials expressed strong interest in the Global Virorne Project (GVP), and said Chinese funding for the project would likely come from Chinese Academy of Sciences funding already earmarked for One Belt, One Road-related initiatives…. GVP aims to launch this year as an international collaborative effort to identify within ten years virtually all of the planet’s viruses that have pandemic or epidemic potential and the ability to jump to humans. “We hope China will be one of the leading countries to initiate the Global Virome Project,” one Wuhan Institute of Virology official said. China attended a GVP unveiling meeting in January in Thailand and is waiting for more details of the initiative. The officials said that the Chinese government funds projects similar to GVP to investigate the background of viruses and bacteria. This essentially constituted China’s own Virome Project …

Also Read: INDIA BLACKLISTED US CDC FOR SECRETLY FUNDING BIOWEAPONS RESEARCH IN MANIPAL

U.S.-China Workshop Explores Research Partnerships

***

 Some workshop participants also expressed skepticism about the Global Virome Project’s (GVP) approach, saying that gaining a predictive understanding of viruses with pandemic potential would require going beyond the GVPs strategy of sample collection, to take an “ecological” approach that considers the virome beyond vertebrate systems to identify mechanisms driving pathogen evolution. A follow-on workshop will be held in June at the University of Berkeley. NSF and NSFC hope to jointly announce a funding call for collaborative projects later this year.

On April 14, 2020, NIH official Marshall Bloom forwarded a Washington Post article by Josh Rogin titled “State Department Cables Warned of Safety Issues at Wuhan Lab Studying Bat Coronaviruses,” and asked a colleague to “Please send to the HCTF [High Containment Task Force]. Thanks!”  

After receiving an article via an email on November 1, 2013, from NIH official Greg Folkers with a cartoon depicting a bat depositing coronavirus particles attacking human ACE2 receptor cells, his colleague, Fauci’s Special Assistant Patricia Conrad writes, “I think we need more slides like this…its too cute!”

A January 19, 2018, State Department cable from the US Embassy in Beijing about the Wuhan Institute of Virology with the subject “China Opens First Bio Safety Level 4 Laboratory” includes a section titled “Unclear Guidelines on Virus Access and a Lack of Trained Talent Impede Research,” which notes in its introduction that “its current productivity is limited by a shortage of highly trained technicians and investigators required to safely operate a BSL-4 laboratory and a lack of clarity in related Chinese government policies and guidelines.”

The memo continues: “To date, WIV [Wuhan Institute of Virology] has obtained permission for research on three viruses: Ebola virus, Nipah virus, and Xinjiang hemorrhagic fever virus (a strain of Crimean Congo hemorrhagic fever found in China’s Xinjiang Province.)”

“These new documents show that funding for the Wuhan Institute was greater than the public has been told,” said Judicial Watch President Tom Fitton. “That it has taken a year and a federal lawsuit to get this first disclosure on COVID and Wuhan is evidence of cover-up by Fauci’s agency.”

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

Sometimes my memes are 3D. And you can own them. Or send them to someone.
You can even eat some of them.
CLICK HERE

By Mark Simone (710 WOR Radio New York) and Silviu “Silview” Costinescu

A very interesting book, find out about it on silview.media

It’s hard to believe but America’s top Infectious Disease Doctor Anthony Fauci has been wrong on the coronavirus pandemic —Every step of the way!

Here is a list of several errors, contradictory statements and dangerous gaffes by NIAID Director Dr. Tony Fauci:

1.) Dr. Fauci says he warned Trump in January that the US was in real trouble but that is not what he said publicly.

In January Dr. Anthony Fauci told Newsmax TV that the United States “did not have to worry” about the coronavirus and that it was“not a major threat.”

2.) Dr. Fauci warned of an apocalyptic coronavirus pandemic — then just weeks later he compared the coronavirus to a bad flu.

3.) Dr. Fauci based all of his predictions on models the that were OFF BY MILLIONS and then later told reporters, “You can’t really rely on models.”

4.) On March 20th Dr. Fauci jumped in and during a press briefing on hydroxychloroquine treatment for coronavirus “corrected” the president saying, “You got to be careful when you say ‘fairly effective.’ It was never done in a clinical trial… It was given to individuals and felt that maybe it worked.”

Exactly two weeks later hydroxychloroquine was deemed the most highly rated treatment for the novel coronavirus in an international poll of more than 6,000 doctors.

5.) Dr. Fauci pushed these garbage models every step of the way.

A month ago Dr. Fauci claimed 1 million to 2 million Americans would die from coronavirus. Then he said 100,000 to 200,000 Americans will die from the virus. Three weeks ago he agreed 81,766 Americans would die from the coronavirus. Then by that Wednesday Then by that Wednesday the experts cut the number of deaths to 60,415 projected deaths. to 60,415 projected deaths.



6.) On Easter Dr. Fauci suggested President Trump. should have shut down the economy in February… When the number of known cases in the US was around 100. Fauci later walked back his attacks.

7.) Dr. Fauci said cruises were OK on March 9th. That was a huge error.

8.) Dr. Fauci said malls, movies and gyms were OK on February 29th. That was another huge mistake.

9.) Dr. Fauci was wrong about the first coronavirus deaths in the country. Dr. Fauci, Dr. Birx and the CDC were off by nearly a month. California officials revealed in Aprilthat a patient in Santa Clara died from coronavirus on February 6th not February 29th.

10.) Dr. Fauci flip-flopped on the mask policies more than surfers on a beach in Australia

Sometimes my memes are 3D. And you can own them. Or send them to someone.
You can even eat some of them.
CLICK HERE

11.) On April 15, 2020, Fauci endorses Tinder hookups, unbelievably.

12.) Dr. Fauci relied on corrupt W.H.O rules to lock down the United States and destroy the US economy. Meanwhile, this delays the herd immunity that is needed to prevent a future outbreak of this deadly virus.

13.) Dr. Fauci and Dr. Birx used the Imperial College Model to persuade President Trump to lock down the entire US economy. The Imperial model has since been confirmed as A COMPLETE FRAUD.

14.) Dr. Fauci warned that Georgia would see a surge in coronavirus cases and deaths by opening their economy too early.

He was wrong again– In fact the opposite happened.

15.) And on Tuesday during testimony Dr. Fauci told Dr. Rand Paul that opening the schools would not be a good idea.

Here comes my update, to top them all:
#0. Anthony Fauci warns of ‘irreparable damage’ if lockdowns are kept in place for too long
12h ago

Humanity shut itself down based on these “experts”…

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them